Pfizer takes ASPIRE program into oncology realm
The expansion of the program will include up to $5.5 million in new competitive grants that will be available to fund the research studies of Pfizer product designed to treat breast and hematologic cancers. The new program will be called the ASPIRE Oncology/Hematology Clinical Research Awards.
“We look forward to enhancing this important grants program in 2017 to further support investigator-initiated efforts in both breast and hematologic cancers where there is a substantial need for research that may lead to improved care,” Pfizer Oncology Senior Director of Medical Affairs Graciela Mabel Woloj said. “Supporting research projects that advance medical and scientific knowledge about our therapies is at the cornerstone of our commitment to meeting the needs of the cancer community.”
Pfizer is encouraging investigators from the United States to submit proposals that deal with innovative clinical research for the assessment of Pfizer compounds focused on the advancement of knowledge for the treatment and disease management of breast cancer and hematologic malignancies. The oral, first-in-class inhibitor IBRANCE should be included in all submitted proposals.